Nektar Therapeutics (NKTR) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $61.56 -7.9%
EPS Growth %: -215.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -215.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.40), in-line with the analyst estimate of ($0.40). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $21.49 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period
- ’Not your father’s Sandisk’: Rosenblatt starts coverage at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
